Pharmaceutical regulatory affairs is the function that translates scientific evidence into regulatory approvals. Companies with sophisticated regulatory teams that understand how to select the optimal approval pathway, generate the most compelling evidence package, engage proactively with regulatory agencies, and manage post-approval commitments efficiently gain a structural competitive advantage that compounds over years of product development. The FDA granted 55 novel drug approvals in 2024, the second-highest total in history. China’s NMPA has reduced review timelines from 5-7 years to 12-18 months for priority products.
Topics Covered
• FDA Expedited Pathways
• FDA Accelerated Approval Reform
• EMA Accelerated Pathways
• China NMPA
• Japan PMDA and Other Key Markets
• Global Submission Strategy
• Post-Approval Regulatory Management
Table of Contents
1. Executive Summary
2. Landscape Overview
3. FDA Expedited Pathways
4. FDA Accelerated Approval Reform
5. EMA Accelerated Pathways
6. China NMPA
7. Japan PMDA and Other Key Markets
8. Global Submission Strategy
9. Post-Approval Regulatory Management
10. Strategic Conclusions and Recommendations
11. Appendix
List of Tables
Table 1. Overview and Key Data 2025
Table 2-8. Topic-Specific Analysis Tables
Table 2. Leading Companies — Strategy Assessment 2025
Table 3. Key Risks and Mitigation Strategies
Companies Profiled
Pfizer
Johnson & Johnson
Roche
Novartis
Merck
AstraZeneca
Bristol-Myers Squibb
AbbVie
Eli Lilly
Sanofi
